Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -945.92% is 18% above its 5-year average of -1150.78%, near the high end of its 5-year range (-3965.99%–-304.25%).
39.85% above its 12-month average of -1572.60%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1708.02%.
NET PROFIT MARGIN
-945.92%
NET PROFIT MARGIN AVG TTM
-1572.60%
NET PROFIT MARGIN AVG 3Y
-1120.85%
NET PROFIT MARGIN AVG 5Y
-1150.78%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+39.85%
CURRENT VS 3Y AVG
+15.61%
CURRENT VS 5Y AVG
+17.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
8.68%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
-10997.70%
vs the sector median at left
Recursion Pharmaceuticals, Inc.
Market Cap
$2.13B
Net Profit Margin
-945.92%
TTM Avg
-1572.60%
3Y Avg
-1120.85%
5Y Avg
-1150.78%
Market Cap
$2.49B
Net Profit Margin
-54.75%
TTM Avg
-325.19%
3Y Avg
-290.00%
5Y Avg
-135445.82%
Market Cap
$1.74B
Net Profit Margin
-14.99%
TTM Avg
-20.12%
3Y Avg
-16.95%
5Y Avg
-10.04%
Market Cap
$1.71B
Net Profit Margin
-672.16%
TTM Avg
-753.31%
3Y Avg
-935.73%
5Y Avg
-797.48%
Market Cap
$2.72B
Net Profit Margin
22.69%
TTM Avg
19.73%
3Y Avg
-2.42%
5Y Avg
-44.65%
Market Cap
$1.01B
Net Profit Margin
-7.13%
TTM Avg
-23.45%
3Y Avg
-155.72%
5Y Avg
-114.72%
Market Cap
$470.35M
Net Profit Margin
-6.77%
TTM Avg
-13.38%
3Y Avg
-17.48%
5Y Avg
-11.79%
Market Cap
$389.98M
Net Profit Margin
-58.33%
TTM Avg
-67.34%
3Y Avg
-66.78%
5Y Avg
-66.78%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.13B | -945.92% | -1572.60% | -1120.85% | -1150.78% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | -54.75% | -325.19% | -290.00% | -135445.82% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | -14.99% | -20.12% | -16.95% | -10.04% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -672.16% | -753.31% | -935.73% | -797.48% |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 22.69% | 19.73% | -2.42% | -44.65% |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | -7.13% | -23.45% | -155.72% | -114.72% |
| NeoGenomics, Inc. (NEO)vs › | $470.35M | -6.77% | -13.38% | -17.48% | -11.79% |
| NRC Health (NRC)vs › | $459.30M | 4.18% | 12.88% | 16.89% | 20.14% |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | -58.33% | -67.34% | -66.78% | -66.78% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-867.9%
Net Profit Margin
-945.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1708.02% |
| 2026-03-31 | -1815.57% |
| 2025-12-31 | -304.25% |
| 2025-09-30 | -3135.32% |
| 2025-06-30 | -899.84% |
| 2025-03-31 | -1373.26% |
| 2024-12-31 | -3965.99% |
| 2024-09-30 | -366.82% |
| 2024-06-30 | -677.17% |
| 2024-03-31 | -677.29% |
| 2023-12-31 | -875.34% |
| 2023-09-30 | -920.78% |
| 2023-06-30 | -696.50% |
| 2023-03-31 | -538.38% |
| 2022-12-31 | -420.39% |
| 2022-09-30 | -463.07% |
| 2022-06-30 | -856.66% |
| 2022-03-31 | -1056.41% |
| 2021-12-31 | -2597.32% |
| 2021-09-30 | -1897.12% |
| 2021-06-30 | -1736.04% |
| 2021-03-31 | -1228.68% |
| 2020-12-31 | -1010.04% |
| 2020-09-30 | -2769.49% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
